Pages that link to "Q35382871"
Jump to navigation
Jump to search
The following pages link to Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors (Q35382871):
Displaying 50 items.
- Increasing the potency and breadth of an HIV antibody by using structure-based rational design (Q24631510) (← links)
- Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals (Q24635002) (← links)
- The HIV glycan shield as a target for broadly neutralizing antibodies (Q26786540) (← links)
- The evolution within us (Q26801603) (← links)
- Structural insights on the role of antibodies in HIV-1 vaccine and therapy (Q26829461) (← links)
- Designing synthetic vaccines for HIV (Q26862617) (← links)
- HIV-1 neutralizing antibodies: understanding nature's pathways (Q27000480) (← links)
- Antibodies in HIV-1 vaccine development and therapy (Q27011574) (← links)
- HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design (Q27022055) (← links)
- Catching HIV 'in the act' with 3D electron microscopy (Q27026806) (← links)
- Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site (Q27319450) (← links)
- Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody (Q27644415) (← links)
- Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 (Q27644478) (← links)
- Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus (Q27644501) (← links)
- Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies (Q27644515) (← links)
- Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design (Q27644634) (← links)
- Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies (Q27674878) (← links)
- Broad and potent neutralization of HIV-1 by a gp41-specific human antibody (Q27675131) (← links)
- Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 (Q27675879) (← links)
- Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth (Q27676728) (← links)
- Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans (Q27678062) (← links)
- Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 (Q27678312) (← links)
- The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies (Q27680688) (← links)
- Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIV (Q27681527) (← links)
- Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization (Q27684578) (← links)
- Progress in HIV-1 vaccine development. (Q27693849) (← links)
- Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies (Q28066335) (← links)
- Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design (Q28084672) (← links)
- Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope (Q28263655) (← links)
- Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies (Q28602877) (← links)
- Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding (Q28728517) (← links)
- Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem (Q30234773) (← links)
- Survivors Remorse: antibody-mediated protection against HIV-1. (Q30238730) (← links)
- Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. (Q30352300) (← links)
- Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1 (Q30353580) (← links)
- HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development (Q30355260) (← links)
- HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual. (Q30393763) (← links)
- Mechanisms of Adaptive Immunity to Porcine Reproductive and Respiratory Syndrome Virus (Q32183108) (← links)
- Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy (Q33611645) (← links)
- Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge (Q33804531) (← links)
- Transplanting supersites of HIV-1 vulnerability (Q33854841) (← links)
- HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities (Q33900395) (← links)
- HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1 (Q33947008) (← links)
- Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination (Q34022578) (← links)
- Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies (Q34114798) (← links)
- Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120. (Q34146374) (← links)
- Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies (Q34177732) (← links)
- Generation and characterization of an HIV-1 subtype C transmitted and early founder virus consensus sequence (Q34266252) (← links)
- B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study (Q34273373) (← links)
- Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum (Q34280115) (← links)